Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$4.13
0.040.98%
At close: -
$4.13
0.000.00%
After Hours: Jun 20, 4:00 PM EDT
Comments
Loading...
4D Molecular Therapeutics Analyst Ratings and Price Targets | NASDAQ:FDMT | Benzinga
4D Molecular Therapeutics Inc has a consensus price target of $31.33 based on the ratings of 13 analysts. The high is $58 issued by Jefferies on April 1, 2024. The low is $6 issued by Morgan Stanley on January 13, 2025. The 3 most-recent analyst ratings were released by Chardan Capital, Goldman Sachs, and Barclays on May 9, 2025, respectively. With an average price target of $35.67 between Chardan Capital, Goldman Sachs, and Barclays, there's an implied 763.60% upside for 4D Molecular Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Chardan Capital
Goldman Sachs
Barclays
B of A Securities
RBC Capital
1calculated from analyst ratings
Analyst Ratings for 4D Molecular Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/09/2025 | Buy Now | 505.33% | Chardan Capital | Geulah Livshits49% | $28 → $25 | Maintains | Buy | Get Alert |
| 05/09/2025 | Buy Now | 965.38% | Goldman Sachs | Salveen Richter51% | $51 → $44 | Maintains | Buy | Get Alert |
| 05/09/2025 | Buy Now | 820.1% | Barclays | Gena Wang51% | $45 → $38 | Maintains | Overweight | Get Alert |
| 03/10/2025 | Buy Now | 868.52% | B of A Securities | Tazeen Ahmad57% | $42 → $40 | Maintains | Buy | Get Alert |
| 03/04/2025 | Buy Now | 577.97% | Chardan Capital | Geulah Livshits49% | $30 → $28 | Maintains | Buy | Get Alert |
| 03/03/2025 | Buy Now | 747.46% | RBC Capital | Luca Issi45% | $39 → $35 | Maintains | Outperform | Get Alert |
| 03/03/2025 | Buy Now | 771.67% | HC Wainwright & Co. | Matthew Caufield38% | $36 → $36 | Reiterates | Buy → Buy | Get Alert |
| 02/11/2025 | Buy Now | 626.39% | Chardan Capital | Geulah Livshits49% | $39 → $30 | Maintains | Buy | Get Alert |
| 02/10/2025 | Buy Now | 771.67% | HC Wainwright & Co. | Matthew Caufield38% | $36 → $36 | Reiterates | Buy → Buy | Get Alert |
| 01/13/2025 | Buy Now | 45.28% | Morgan Stanley | Judah Frommer65% | $8 → $6 | Maintains | Underweight | Get Alert |
| 01/13/2025 | Buy Now | 553.75% | Leerink Partners | Mani Foroohar50% | $31 → $27 | Maintains | Outperform | Get Alert |
| 01/13/2025 | Buy Now | 771.67% | HC Wainwright & Co. | Matthew Caufield38% | $36 → $36 | Reiterates | Buy → Buy | Get Alert |
| 12/18/2024 | Buy Now | 1013.8% | B of A Securities | Tazeen Ahmad57% | $79 → $46 | Maintains | Buy | Get Alert |
| 11/21/2024 | Buy Now | 93.7% | Morgan Stanley | Judah Frommer65% | → $8 | Initiates | → Underweight | Get Alert |
| 11/14/2024 | Buy Now | 844.31% | Chardan Capital | Geulah Livshits49% | $39 → $39 | Maintains | Buy | Get Alert |
| 11/14/2024 | Buy Now | 771.67% | HC Wainwright & Co. | Matthew Caufield38% | $36 → $36 | Reiterates | Buy → Buy | Get Alert |
| 11/14/2024 | Buy Now | 844.31% | RBC Capital | Luca Issi45% | $40 → $39 | Maintains | Outperform | Get Alert |
| 09/23/2024 | Buy Now | — | Cantor Fitzgerald | Josh Schimmer56% | — | Downgrade | Overweight → Neutral | Get Alert |
| 09/19/2024 | Buy Now | 844.31% | Chardan Capital | Geulah Livshits49% | $38 → $39 | Maintains | Buy | Get Alert |
| 09/19/2024 | Buy Now | 771.67% | Leerink Partners | Mani Foroohar50% | $40 → $36 | Reiterates | Outperform → Outperform | Get Alert |
| 09/19/2024 | Buy Now | 771.67% | HC Wainwright & Co. | Matthew Caufield38% | $36 → $36 | Reiterates | Buy → Buy | Get Alert |
| 09/09/2024 | Buy Now | — | Cantor Fitzgerald | Josh Schimmer56% | — | Reiterates | → Overweight | Get Alert |
| 08/09/2024 | Buy Now | 771.67% | HC Wainwright & Co. | Matthew Caufield38% | $36 → $36 | Reiterates | Buy → Buy | Get Alert |
| 07/22/2024 | Buy Now | 868.52% | RBC Capital | Luca Issi45% | $40 → $40 | Reiterates | Outperform → Outperform | Get Alert |
| 07/18/2024 | Buy Now | 868.52% | BMO Capital | Kostas Biliouris33% | $63 → $40 | Maintains | Outperform | Get Alert |
| 07/17/2024 | Buy Now | 820.1% | Chardan Capital | Geulah Livshits49% | $38 → $38 | Maintains | Buy | Get Alert |
| 06/26/2024 | Buy Now | 868.52% | RBC Capital | Luca Issi45% | $40 → $40 | Reiterates | Outperform → Outperform | Get Alert |
| 06/07/2024 | Buy Now | 771.67% | HC Wainwright & Co. | Matthew Caufield38% | $36 → $36 | Reiterates | Buy → Buy | Get Alert |
| 05/13/2024 | Buy Now | 771.67% | HC Wainwright & Co. | Matthew Caufield38% | $36 → $36 | Reiterates | Buy → Buy | Get Alert |
| 04/15/2024 | Buy Now | 868.52% | RBC Capital | Luca Issi45% | $35 → $40 | Maintains | Outperform | Get Alert |
| 04/15/2024 | Buy Now | 989.59% | Barclays | Gena Wang51% | → $45 | Initiates | → Overweight | Get Alert |
| 04/01/2024 | Buy Now | 1425.42% | BMO Capital | Kostas Biliouris33% | $70 → $63 | Maintains | Outperform | Get Alert |
| 04/01/2024 | Buy Now | 1304.36% | Jefferies | Nalin Tejavibulya54% | $30 → $58 | Maintains | Buy | Get Alert |
| 03/01/2024 | Buy Now | 771.67% | HC Wainwright & Co. | Matthew Caufield38% | $36 → $36 | Reiterates | Buy → Buy | Get Alert |
| 02/07/2024 | Buy Now | 1861.26% | Goldman Sachs | Salveen Richter51% | → $81 | Reinstates | → Buy | Get Alert |
| 02/05/2024 | Buy Now | 1594.92% | BMO Capital | Kostas Biliouris33% | $50 → $70 | Maintains | Outperform | Get Alert |
| 02/05/2024 | Buy Now | 747.46% | RBC Capital | Luca Issi45% | $25 → $35 | Maintains | Outperform | Get Alert |
| 01/29/2024 | Buy Now | 505.33% | RBC Capital | Luca Issi45% | → $25 | Reiterates | Outperform → Outperform | Get Alert |
| 10/24/2023 | Buy Now | 674.82% | Cantor Fitzgerald | Josh Schimmer56% | → $32 | Initiates | → Overweight | Get Alert |
| 08/11/2023 | Buy Now | 650.61% | Chardan Capital | Geulah Livshits49% | → $31 | Reiterates | Buy → Buy | Get Alert |
| 08/10/2023 | Buy Now | 771.67% | HC Wainwright & Co. | Matthew Caufield38% | → $36 | Reiterates | Buy → Buy | Get Alert |
| 07/31/2023 | Buy Now | 771.67% | HC Wainwright & Co. | Matthew Caufield38% | → $36 | Reiterates | Buy → Buy | Get Alert |
| 07/11/2023 | Buy Now | 650.61% | Chardan Capital | Geulah Livshits49% | $30 → $31 | Maintains | Buy | Get Alert |
| 07/05/2023 | Buy Now | 626.39% | Chardan Capital | Geulah Livshits49% | → $30 | Initiates | → Buy | Get Alert |
| 06/08/2023 | Buy Now | 699.03% | B of A Securities | Tazeen Ahmad57% | $28 → $33 | Maintains | Buy | Get Alert |
| 06/08/2023 | Buy Now | 771.67% | HC Wainwright & Co. | Matthew Caufield38% | → $36 | Reiterates | Buy → Buy | Get Alert |
| 05/11/2023 | Buy Now | 771.67% | HC Wainwright & Co. | Matthew Caufield38% | → $36 | Reiterates | Buy → Buy | Get Alert |
| 04/28/2023 | Buy Now | 771.67% | HC Wainwright & Co. | Matthew Caufield38% | → $36 | Reiterates | → Buy | Get Alert |
| 04/13/2023 | Buy Now | 214.77% | SVB Securities | Mani Foroohar50% | $14 → $13 | Maintains | Market Perform | Get Alert |
| 03/16/2023 | Buy Now | 771.67% | HC Wainwright & Co. | Matthew Caufield38% | → $36 | Reiterates | → Buy | Get Alert |
| 02/23/2023 | Buy Now | 771.67% | HC Wainwright & Co. | Matthew Caufield38% | → $36 | Reiterates | → Buy | Get Alert |
| 02/06/2023 | Buy Now | 771.67% | HC Wainwright & Co. | Matthew Caufield38% | → $36 | Reiterates | → Buy | Get Alert |
| 02/06/2023 | Buy Now | 238.98% | SVB Leerink | Mani Foroohar50% | $15 → $14 | Maintains | Market Perform | Get Alert |
| 01/30/2023 | Buy Now | 1110.65% | BMO Capital | Kostas Biliouris33% | → $50 | Initiates | → Outperform | Get Alert |
| 11/18/2022 | Buy Now | 771.67% | HC Wainwright & Co. | Matthew Caufield38% | → $36 | Initiates | → Buy | Get Alert |
| 11/15/2022 | Buy Now | 1546.49% | Goldman Sachs | Salveen Richter51% | → $68 | Upgrade | Neutral → Buy | Get Alert |
| 11/14/2022 | Buy Now | 263.2% | SVB Leerink | Mani Foroohar50% | $11 → $15 | Maintains | Market Perform | Get Alert |
| 11/10/2022 | Buy Now | 166.34% | SVB Leerink | Mani Foroohar50% | $10 → $11 | Maintains | Market Perform | Get Alert |
| 08/12/2022 | Buy Now | 190.56% | SVB Leerink | Mani Foroohar50% | $28 → $12 | Downgrade | Outperform → Market Perform | Get Alert |
| 06/22/2022 | Buy Now | 432.69% | Jefferies | Nalin Tejavibulya54% | → $22 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for 4D Molecular Therapeutics (FDMT) stock?
The latest price target for 4D Molecular Therapeutics (NASDAQ:FDMT) was reported by Chardan Capital on May 9, 2025. The analyst firm set a price target for $25.00 expecting FDMT to rise to within 12 months (a possible 505.33% upside). 27 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for 4D Molecular Therapeutics (FDMT)?
The latest analyst rating for 4D Molecular Therapeutics (NASDAQ:FDMT) was provided by Chardan Capital, and 4D Molecular Therapeutics maintained their buy rating.
When was the last upgrade for 4D Molecular Therapeutics (FDMT)?
The last upgrade for 4D Molecular Therapeutics Inc happened on November 15, 2022 when Goldman Sachs raised their price target to $68. Goldman Sachs previously had a neutral for 4D Molecular Therapeutics Inc.
When was the last downgrade for 4D Molecular Therapeutics (FDMT)?
The last downgrade for 4D Molecular Therapeutics Inc happened on September 23, 2024 when Cantor Fitzgerald changed their price target from N/A to N/A for 4D Molecular Therapeutics Inc.
When is the next analyst rating going to be posted or updated for 4D Molecular Therapeutics (FDMT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of 4D Molecular Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for 4D Molecular Therapeutics was filed on May 9, 2025 so you should expect the next rating to be made available sometime around May 9, 2026.
Is the Analyst Rating 4D Molecular Therapeutics (FDMT) correct?
While ratings are subjective and will change, the latest 4D Molecular Therapeutics (FDMT) rating was a maintained with a price target of $28.00 to $25.00. The current price 4D Molecular Therapeutics (FDMT) is trading at is $4.13, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
